# Assembly Biosciences Inc. (ASMB)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $248M  
**Price:** $22.10 (-0.72%)

> Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics for serious viral diseases worldwide. Its pipeline features long-acting helicase-primase inhibitors ABI-5366 and ABI-1179, currently in Phase 1a/1b clinical studies targeting recurrent genital herpes caused by herpes simplex virus. The company is also advancing ABI-4334, a next-generation capsid assembly modulator in Phase 1b trials designed to disrupt the hepatitis B virus replication cycle, and ABI-6250, an oral hepatitis delta virus entry inhibitor in Phase 1a studies. Additional candidates include ABI-7272, a broad-spectrum non-nucleoside polymerase inhibitor for transplant-related herpesviruses. Assembly Biosciences Inc. leverages expertise in virology to create innovative oral therapies aimed at improving treatment outcomes for patients with chronic viral infections like hepatitis B and delta, as well as herpesviruses. Founded in 2005 and headquartered in South San Francisco, California, the company plays a key role in the biotechnology sector by addressing unmet needs in antiviral drug development.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $72M | — | -$12M | -$6M | — |
| 2024 | $29M | — | -$45M | -$40M | — |
| 2023 | $7M | — | -$65M | -$61M | — |
| 2022 | — | — | -$94M | -$93M | — |
| 2021 | $6M | — | -$133M | -$130M | — |
| 2020 | $79M | — | -$65M | -$62M | — |
| 2019 | $16M | — | -$103M | -$98M | — |
| 2018 | $15M | — | -$93M | -$91M | — |
| 2017 | $9M | — | -$52M | -$43M | — |
| 2016 | — | — | -$45M | -$44M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $258M | $51M | $207M | $58M | — |
| 2024 | $119M | $86M | $33M | $38M | — |
| 2023 | $137M | $96M | $41M | $20M | — |
| 2022 | $102M | $19M | $83M | $52M | — |
| 2021 | $191M | $22M | $169M | $46M | — |
| 2020 | $283M | $43M | $241M | $59M | — |
| 2019 | $340M | $67M | $273M | $47M | — |
| 2018 | $268M | $57M | $211M | $41M | — |
| 2017 | $169M | $56M | $113M | $82M | — |
| 2016 | $98M | $18M | $80M | $29M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$41M | $66,000 | -$41M |
| 2024 | -$51M | $28,000 | -$51M |
| 2023 | $23M | $255,000 | $22M |
| 2022 | -$84M | $102,000 | -$85M |
| 2021 | -$93M | $3M | -$96M |
| 2020 | -$63M | $470,000 | -$63M |
| 2019 | -$84M | $2M | -$86M |
| 2018 | -$65M | $340,000 | -$65M |
| 2017 | $2M | $865,000 | $995,000 |
| 2016 | -$35M | $147,000 | -$35M |
| 2015 | -$19M | $58,261 | -$19M |
| 2014 | -$15M | $149,963 | -$15M |
| 2013 | -$18M | $6,477 | -$18M |
| 2012 | -$21M | $3,241 | -$21M |
| 2011 | -$25M | $11,964 | -$25M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ASMB)